Arbutus Biopharma Analyst Ratings
Arbutus Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/12/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/04/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/04/2023 | 172.73% | Chardan Capital | → $6 | Reiterates | Buy → Buy |
| 07/11/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 07/06/2023 | 172.73% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 06/22/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 06/22/2023 | 172.73% | Chardan Capital | → $6 | Reiterates | Buy → Buy |
| 05/05/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 04/28/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 04/05/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/29/2023 | 172.73% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 03/20/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/03/2023 | 172.73% | Chardan Capital | → $6 | Reiterates | → Buy |
| 03/03/2023 | 172.73% | HC Wainwright & Co. | → $6 | Maintains | Buy |
| 11/10/2022 | 172.73% | HC Wainwright & Co. | $7.5 → $6 | Maintains | Buy |
| 06/28/2022 | 309.09% | JMP Securities | $10 → $9 | Maintains | Market Outperform |
| 03/14/2022 | 286.36% | HC Wainwright & Co. | $8 → $8.5 | Maintains | Buy |
| 03/04/2022 | 172.73% | Chardan Capital | $5.5 → $6 | Maintains | Buy |
| 02/02/2022 | 127.27% | Jefferies | $4 → $5 | Upgrades | Hold → Buy |
| 11/08/2021 | 309.09% | JMP Securities | $7 → $9 | Maintains | Market Outperform |
| 12/17/2020 | 354.55% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 07/24/2020 | — | Baird | Downgrades | Outperform → Neutral | |
| 05/19/2020 | 81.82% | Wedbush | $2 → $4 | Upgrades | Neutral → Outperform |
| 03/27/2020 | 81.82% | Baird | $8 → $4 | Maintains | Outperform |
| 03/06/2020 | 127.27% | Chardan Capital | $1.5 → $5 | Upgrades | Neutral → Buy |
| 02/20/2020 | 263.64% | Baird | → $8 | Initiates Coverage On | → Outperform |
| 02/05/2020 | 354.55% | JMP Securities | → $10 | Upgrades | Market Perform → Market Outperform |
| 01/09/2020 | 172.73% | B. Riley Securities | $3 → $6 | Maintains | Buy |
| 10/04/2019 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 10/16/2018 | 309.09% | B. Riley Securities | $11.5 → $9 | Upgrades | Neutral → Buy |
| 10/15/2018 | 127.27% | Wedbush | → $5 | Upgrades | Underperform → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/12/2023 | 172.73% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 08/04/2023 | 172.73% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 08/04/2023 | 172.73% | 查爾丹資本 | →$6 | 重申 | 購買→購買 |
| 07/11/2023 | 172.73% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 07/06/2023 | 172.73% | JMP證券 | →$6 | 重申 | 市場表現優於→市場表現 |
| 2023/06/22 | 172.73% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 2023/06/22 | 172.73% | 查爾丹資本 | →$6 | 重申 | 購買→購買 |
| 05/05/2023 | 172.73% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 04/28/2023 | 172.73% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 04/05/2023 | 172.73% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 03/29/2023 | 172.73% | JMP證券 | →$6 | 重申 | →市場跑贏大盤 |
| 03/20/2023 | 172.73% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 03/03/2023 | 172.73% | 查爾丹資本 | →$6 | 重申 | →購買 |
| 03/03/2023 | 172.73% | HC Wainwright公司 | →$6 | 維護 | 買 |
| 2022年11月10日 | 172.73% | HC Wainwright公司 | $7.5→$6 | 維護 | 買 |
| 2022/06/28 | 309.09% | JMP證券 | $10→$9 | 維護 | 市場表現強於大盤 |
| 03/14/2022 | 286.36% | HC Wainwright公司 | $8→$8.5 | 維護 | 買 |
| 03/04/2022 | 172.73% | 查爾丹資本 | $5.5→$6 | 維護 | 買 |
| 02/02/2022 | 127.27% | 傑富瑞 | $4→$5 | 升級 | 持有→購買 |
| 11/08/2021 | 309.09% | JMP證券 | $7→$9 | 維護 | 市場表現強於大盤 |
| 12/17/2020 | 354.55% | HC Wainwright公司 | →$10 | 開始承保 | →購買 |
| 07/24/2020 | - | 貝爾德 | 評級下調 | 跑贏→中性 | |
| 2020/05/19 | 81.82% | 韋德布什 | $2→$4 | 升級 | 中性→表現優異 |
| 03/27/2020 | 81.82% | 貝爾德 | $8→$4 | 維護 | 跑贏大盤 |
| 03/06/2020 | 127.27% | 查爾丹資本 | $1.5→$5 | 升級 | 中性→購買 |
| 02/20/2020 | 263.64% | 貝爾德 | →$8 | 開始承保 | →跑贏大盤 |
| 02/05/2020 | 354.55% | JMP證券 | →$10 | 升級 | 市場表現優於→市場表現 |
| 1/09/2020 | 172.73% | B.萊利證券 | $3→$6 | 維護 | 買 |
| 2019/10/04 | - | 查爾丹資本 | 評級下調 | 購買→中性 | |
| 2018年10月16日 | 309.09% | B.萊利證券 | $11.5→$9 | 升級 | 中性→購買 |
| 2018年10月15日 | 127.27% | 韋德布什 | →$5 | 升級 | 表現不佳的→中性 |
What is the target price for Arbutus Biopharma (ABUS)?
楊樹的目標價是多少？
The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 172.73% upside). 15 analyst firms have reported ratings in the last year.
納斯達克(納斯達克代碼：ABUS)的最新目標價是由HC Wainwright&Co.於2023年9月12日報道的。這家分析公司將目標價定為6美元，預計abus將在12個月內上漲(可能上漲172.73%)。過去一年，有15家分析公司公佈了評級。
What is the most recent analyst rating for Arbutus Biopharma (ABUS)?
Abutus Biophma(ABUS)最近的分析師評級是多少？
The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.
納斯達克(股票代碼：ABUS)的最新分析師評級由HC Wainwright&Co.提供，Arbutus Biophma重申其買入評級。
When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?
下一次分析師評級將在什麼時候發佈或更新楊樹(ABUS)？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Arbutus Biophma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Arbutus Biophma的上一次評級是在2023年9月12日提交的，所以你應該預計下一次評級將在2024年9月12日左右的某個時候公佈。
Is the Analyst Rating Arbutus Biopharma (ABUS) correct?
分析師對Arbutus Biophma(ABUS)的評級正確嗎？
While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.20, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Arbutus Biophma(ABUS)評級被重申，目標價在0.00美元至6.00美元之間。Arbutus Biophma(ABUS)目前的交易價格為2.20美元，在分析師的預測範圍內。